Anixa Biosciences Inc (ANIX) Stock Price, Quote & News

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 708 9808

Website: www.anixa.com

Address:

3150 Almaden Expressway, Suite 250, San Jose, United States

OfficialStocktwitsUser May. 12 at 3:40 AM

$ANIX RSI: 56.00, MACD: 0.0543 Vol: 0.08, MA20: 2.99, MA50: 2.85 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

bioinvestorrr May. 11 at 1:24 PM

$ANIX great news, curious to see movement

1 · Reply

Kher33 May. 11 at 12:56 PM

$ANIX

0 · Reply

Stock_Catcher May. 11 at 12:55 PM

$ANIX Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy

0 · Reply

justiceforb_85 May. 8 at 3:34 AM

$ANIX when is their next clinical update on the breast cancer vaccine? Science behind it is intriguing but it's extremely early stage.

0 · Reply

Stocktradexxx May. 4 at 8:18 PM

$ANIX great article highlighting Anixa's breast cancer vaccine- https://www.wptv.com/news/treasure-coast/patient-who-received-breast-cancer-vaccine-as-part-of-clinical-trial-speaks-about-experience

0 · Reply

SCUBus May. 2 at 7:52 PM

$ANIX Anybody else planning to watch CEO Amit Kumar speak on Bloomberg TV tonight between 7 - 7:30 PM? Apparently he is one of two companies being interviewed. RedChip Companies will air interviews with Anixia Biosciences, Inc. (NASDAQ:ANIX) on the RedChip Small Stocks, Big Money show on Bloomberg TV Saturday, May 2, at 7 p.m. Eastern Time. Bloomberg TV is available in an estimated 73 million homes across the U.S.

1 · Reply

Pedelco Apr. 30 at 1:58 PM

$ANIX back to 5$

0 · Reply

Kher33 Apr. 30 at 10:29 AM

$ANIX https://ir.anixa.com/press-releases/detail/1122

0 · Reply

KONGLIVES1 Apr. 29 at 2:17 PM

$ANIX I would love to know where this information is on the Mexican patent available so I can read about it myself. Thank you. Enjoy the ride.

1 · Reply

Anixa Biosciences’ lira-cel shows positive survival data in ovarian cancer

May 11, 2026, 8:55 AM EDT - 1 day ago

Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy

May 1, 2026, 9:15 AM EDT - 11 days ago

Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

2026-04-29T13:17:16.000Z - 13 days ago

Anixa Biosciences awarded patent for breast cancer vaccine in Mexico

Apr 29, 2026, 9:10 AM EDT - 13 days ago

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

Apr 22, 2026, 8:45 AM EDT - 20 days ago

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting

Apr 14, 2026, 12:30 PM EDT - 4 weeks ago

Anixa Biosciences Transcript: Water Tower Research Insights Conference

Apr 9, 2026, 9:05 AM EDT - 4 weeks ago

Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026

Apr 7, 2026, 8:55 AM EDT - 5 weeks ago

Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026

Apr 6, 2026, 9:10 AM EDT - 5 weeks ago

Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs

2026-04-01T12:59:01.000Z - 5 weeks ago

Anixa Biosciences announces agreement with Cytovance Biologics

Apr 1, 2026, 8:50 AM EDT - 5 weeks ago

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

Mar 30, 2026, 9:05 AM EDT - 6 weeks ago

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer

Mar 12, 2026, 10:38 AM EDT - 2 months ago

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

Mar 10, 2026, 1:00 PM EDT - 2 months ago

Anixa Biosciences Transcript: AGM 2026

2026-03-09T12:36:09.000Z - 2 months ago

Anixa Biosciences says Korean MOIP issues Notice of Allowance for new patent

Mar 9, 2026, 8:30 AM EDT - 2 months ago

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Mar 2, 2026, 9:10 AM EST - 2 months ago

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Feb 23, 2026, 8:55 AM EST - 2 months ago

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Feb 10, 2026, 11:00 AM EST - 3 months ago

Anixa Biosciences Transcript: Fireside chat

2026-02-09T13:05:35.000Z - 3 months ago

Anixa provides update on Phase 1 ovarian cancer CAR-T clinical trial

Feb 9, 2026, 8:00 AM EST - 3 months ago

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

2026-02-02T14:10:54.000Z - 3 months ago

Anixa Biosciences receives USAN Council approval for novel CAR-T therapy name

Feb 2, 2026, 9:00 AM EST - 3 months ago

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

2026-01-27T13:36:37.000Z - 3 months ago

Anixa Biosciences granted patent for breast cancer vaccine technology in Mexico

Jan 27, 2026, 8:30 AM EST - 3 months ago

Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

Jan 21, 2026, 3:54 PM EST - 3 months ago

Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa's T-Cell Innovations Show Breakthrough Potential in Solid Tumors”

Dec 15, 2025, 1:00 PM EST - 5 months ago

Anixa Biosciences Transcript: Water Tower Research Fireside Chat Series

2025-12-15T13:51:02.000Z - 5 months ago

Anixa announces transfer of IND for breast cancer vaccine from Cleveland Clinic

Dec 15, 2025, 8:45 AM EST - 5 months ago

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

2025-12-11T23:05:21.000Z - 5 months ago

Anixa Biosciences says all primary endpoints met in breast cancer vaccine trial

Dec 11, 2025, 6:02 PM EST - 5 months ago

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Dec 10, 2025, 9:00 AM EST - 5 months ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

2025-11-17T13:20:42.000Z - 6 months ago

Anixa Biosciences’ CAR-T therapy granted WHO approval of non-proprietary name

Nov 17, 2025, 8:15 AM EST - 6 months ago

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Nov 12, 2025, 11:00 AM EST - 6 months ago

Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat

2025-11-12T14:05:48.000Z - 6 months ago

Anixa Biosciences awarded patent covering breast cancer vaccine technology

Nov 12, 2025, 9:00 AM EST - 6 months ago

Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Nov 11, 2025, 2:00 PM EST - 6 months ago

Anixa Biosciences Transcript: Fireside Chat

Nov 10, 2025, 10:30 AM EST - 6 months ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

2025-11-05T14:01:35.000Z - 6 months ago

Anixa Biosciences executes data transfer with Cleveland Clinic

Nov 5, 2025, 8:55 AM EST - 6 months ago

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Oct 23, 2025, 8:45 AM EDT - 7 months ago

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

2025-10-20T12:30:48.000Z - 7 months ago

Anixa awarded patent in China covering breast cancer vaccine technology

Oct 20, 2025, 8:25 AM EDT - 7 months ago

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

2025-10-07T12:35:32.000Z - 7 months ago

Anixa Biosciences completes patient visit in breast cancer vaccine trial

Oct 7, 2025, 8:30 AM EDT - 7 months ago

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

2025-09-22T12:15:34.000Z - 8 months ago

Anixa announces final results from Phase 1 trial of breast cancer vaccine

Sep 22, 2025, 8:05 AM EDT - 8 months ago

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

2025-09-10T21:30:21.000Z - 8 months ago

Anixa Biosciences files $200M mixed securities shelf

Sep 9, 2025, 10:30 AM EDT - 8 months ago

Anixa Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

2025-09-08T12:15:30.000Z - 8 months ago

Anixa completes dosing of fourth cohort in Phase 1 trial of CAR-T/CER-T therapy

Sep 8, 2025, 8:00 AM EDT - 8 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Sep 2, 2025, 8:54 AM EDT - 9 months ago

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 9:13 AM EDT - 9 months ago

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-20T12:40:25.000Z - 9 months ago

Anixa receives notice of allowance in China for cancer vaccine technology patent

Aug 20, 2025, 8:37 AM EDT - 9 months ago

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

2025-08-18T13:10:44.000Z - 9 months ago

Anixa Biosciences treats second patient in fourth ovarian cancer trial cohort

Aug 18, 2025, 9:00 AM EDT - 9 months ago

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

2025-08-12T12:11:13.000Z - 9 months ago

Anixa Biosciences issued additional U.S. patent for CAR-T technology

Aug 12, 2025, 8:05 AM EDT - 9 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Aug 8, 2025, 9:15 AM EDT - 9 months ago

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Aug 4, 2025, 8:45 AM EDT - 10 months ago

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Jul 30, 2025, 8:15 AM EDT - 10 months ago

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Jul 24, 2025, 8:00 AM EDT - 10 months ago

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Jul 9, 2025, 8:00 AM EDT - 11 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Jun 26, 2025, 2:00 PM EDT - 11 months ago

Anixa Biosciences Transcript: Status Update

Jun 23, 2025, 8:00 AM EDT - 11 months ago

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Jun 20, 2025, 7:30 AM EDT - 11 months ago

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Jun 10, 2025, 7:00 AM EDT - 1 year ago

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025

Jun 3, 2025, 7:25 AM EDT - 1 year ago

Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

May 20, 2025, 11:00 AM EDT - 1 year ago

Anixa Biosciences Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 19, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

May 12, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

OfficialStocktwitsUser May. 12 at 3:40 AM

0 · Reply

bioinvestorrr May. 11 at 1:24 PM

$ANIX great news, curious to see movement

1 · Reply

Kher33 May. 11 at 12:56 PM

$ANIX

0 · Reply

Stock_Catcher May. 11 at 12:55 PM

$ANIX Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy

0 · Reply

justiceforb_85 May. 8 at 3:34 AM

$ANIX when is their next clinical update on the breast cancer vaccine? Science behind it is intriguing but it's extremely early stage.

0 · Reply

Stocktradexxx May. 4 at 8:18 PM

$ANIX great article highlighting Anixa's breast cancer vaccine- https://www.wptv.com/news/treasure-coast/patient-who-received-breast-cancer-vaccine-as-part-of-clinical-trial-speaks-about-experience

0 · Reply

SCUBus May. 2 at 7:52 PM

1 · Reply

Pedelco Apr. 30 at 1:58 PM

$ANIX back to 5$

0 · Reply

Kher33 Apr. 30 at 10:29 AM

$ANIX https://ir.anixa.com/press-releases/detail/1122

0 · Reply

KONGLIVES1 Apr. 29 at 2:17 PM

$ANIX I would love to know where this information is on the Mexican patent available so I can read about it myself. Thank you. Enjoy the ride.

1 · Reply

focafoca99 Apr. 29 at 2:01 PM

$ANIX received a Mexican patent covering its breast cancer vaccine technology, extending protection in that market into 2040.

0 · Reply

idkmikes57 Apr. 27 at 8:34 PM

$ANIX b******* head fakes tomorrow i'm dumping this

1 · Reply

KONGLIVES1 Apr. 27 at 8:20 PM

$ANIX I used today as a buying opportunity. Good luck to all enjoy the ride.

0 · Reply

KONGLIVES1 Apr. 27 at 8:16 PM

$ANIX the only good thing about this stock today was the volume good luck enjoy the ride

0 · Reply

Ralphbeach Apr. 26 at 10:17 AM

$ANIX Hidden Gem. Way undervalued. Key Partnerships and Collaborations Cleveland Clinic: Co-developer of Anixa’s breast cancer vaccine (targeting TNBC) and ovarian cancer vaccine, based on technologies from Dr. Vincent Tuohy and others. Moffitt Cancer Center: Collaborator on the chimeric endocrine receptor T-cell (CER-T) technology, a novel CAR-T for ovarian cancer. Analyst Sentiment: The stock has received a "Buy" rating (Zacks Rank #2) and analyst price targets suggest significant upside, ranging from $7.X to $14.

1 · Reply

idkmikes57 Apr. 25 at 5:57 AM

$ANIX okay, here comes the notorious head fake l o l.

0 · Reply

EK12 Apr. 23 at 12:15 PM

$ANIX I have been following this stock daily. There is something brewing up... Not presentation or a marketing press release, but rather someting more substantive. This stock should move over 5 with any Phase II news or new big pharma partnership.

2 · Reply

focafoca99 Apr. 22 at 6:41 PM

$ANIX announced an ovarian cancer CAR-T presentation at the ISCT 2026 annual meeting.

0 · Reply

EK12 Apr. 22 at 6:37 PM

$ANIX Any expected news re: Phase II? Higher price on higher volume any idea?

0 · Reply

idkmikes57 Apr. 10 at 3:56 AM

$ANIX head fake becoming familiar.

0 · Reply

jshdn Apr. 7 at 7:27 PM

$ANIX what do all think of this analysis? https://pharmadevicenews.com/why-anixa-biosciences-phase-2-breast-cancer-vaccine-push-matters-more-than-the-manufacturing-deal-itself/

0 · Reply

bioinvestorrr Apr. 7 at 12:51 PM

$ANIX interesting pre market, wont hold tho

0 · Reply

Market Cap	101.59M
Revenue (ttm)	0.00
Net Income (ttm)	-10.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	108,900
Avg Vol	111,074
Day's Range	N/A - N/A
Shares Out	33.53M
Stochastic %K	31%
Beta	0.64
Analysts	Strong Sell
Price Target	$10.00